Biopharma
By
Biotech Licensing Soars to $137B in 2025 – China Now Leads the Licensing Race
The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to…
RecovryAI’s FDA Breakthrough: Post-Op AI Agents’ 85% Complication Prediction or Wearable Hype Meets Reality?
RecovryAI snared FDA Breakthrough Device Designation on March 4, 2026, for its physician-prescribed Virtual Care Assistants—AI agents that…
Gilead’s $8B Arcellx CAR-T Swoop & Lilly Zepbound Triumph: Obesity/CAR-T Mania or Bubble Burst Ahead?
Gilead’s March 2026 $8B acquisition of Arcellx—securing CAR-T anito-cel for multiple myeloma with 73% ORR Phase 1b data—and…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
